Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide

BACKGROUND: Androgen receptor (AR) signaling inhibitors represent the standard treatment in metastatic castration resistance prostate cancer (mCRPC) patients. However, some patients display a primary resistance, and several studies investigated the role of the AR as a predictive biomarker of respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Re, M., Conteduca, V., Crucitta, S., Gurioli, G., Casadei, C., Restante, G., Schepisi, G., Lolli, C., Cucchiara, F., Danesi, R., De Giorgi, U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134038/
https://www.ncbi.nlm.nih.gov/pubmed/33500577
http://dx.doi.org/10.1038/s41391-020-00309-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134038/
https://www.ncbi.nlm.nih.gov/pubmed/33500577
http://dx.doi.org/10.1038/s41391-020-00309-w

Ejemplares similares